CONCLUSION: IBD/IBS+ affect scoring of IBD disease activity scales and become less useful in guiding treatment plans.
Patients fulfilling IBS criteria had higher hospital anxiety and depression scale (HADS). 29% of patients in deep remission were mis-categorized by HBI/UCDAI as having active disease when they fulfilled Rome III criteria for IBS. Significantly higher HBI/UCDAI scores (p = 0.005) and low short inflammatory bowel disease questionnaire (SIBDQ) scores (p ≤ 0.0001) were seen in IBD/IBS+ patients. RESULTS: 36% (28/77) and 37% (7/19) of CD and UC patients, respectively, met diagnostic criteria for IBS. Other demographic and disease specific data were collected. 96/112 patients with colonoscopy and histology confirmed quiescent disease consented and completed Rome III criteria for IBS Survey, and the hospital anxiety and depression scale (HADS).
METHODS: This was a prospective study at a single tertiary care IBD center. The aims were (1) to determine the percentage of IBD patients in deep remission whose persistent IBS-like symptoms (IBD/IBS+) would cause them to be classified as having active disease, based on the calculation of Harvey Bradshaw Index (HBI) or UC disease activity index (UCDAI) (2) to identify demographic and disease characteristics that are associated with IBD/IBS+. Few prevalence studies of IBS in quiescent IBD have used colonoscopy with histology to confirm inactive disease. , Doenças Inflamatórias Intestinais/diagnósticoīACKGROUND: Inflammatory bowel disease (IBD Crohn's disease, CD and Ulcerative colitis, UC) and irritable bowel syndrome (IBS) have overlapping symptoms.
CONCLUSION: The SPARC IBD is an ongoing large prospective cohort with longitudinal standardized collection of clinical data, biosamples, and PROs representing a unique resource aimed to drive discovery of clinical and molecular markers that will meet the needs of precision medicine in IBD. The overall agreement for CD behavior was 83%. There was 91% overall agreement describing UC extent as left-sided vs extensive or pancolitis. In the quality study of the cohort, there was 96% agreement on year of diagnosis and 97% agreement on IBD subtype. Remission rates were 63.9% in the CD group and 80.6% in the UC group. Among patients enrolled, 990 underwent colonoscopy. RESULTS: Through January 2020, 3029 patients were enrolled in SPARC, of whom 66.1% have Crohn's disease (CD), 32.2% have ulcerative colitis (UC), and 1.7% have IBD-unclassified. The quality of clinical data entry after the first year of the study was assessed. Patient-reported outcomes are collected quarterly. At enrollment and at time of lower endoscopy, patient-reported outcomes (PRO), clinical data, and endoscopy scoring indices are captured. METHODS: We established a cohort of adults with IBD from a geographically diverse sample of patients across the United States with standardized data and biosample collection methods and sample processing techniques. We aimed to develop a study of a prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical and patient-reported data and biosamples. BACKGROUND: Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms of disease and predictors of response and disease relapse.